Peter Thuss-Patience

15PUBLICATIONS
82CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Social epidemiologyTe mana motuhake o ngā raraunga Māori (Māori data sovereignty)Major global burdens of diseaseApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Feb 17, 2026
Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma.

Jun Okui, Satoru Matsuda, Kengo Nagashima

|Jan 07, 2026
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials.

Jun Okui, Satoru Matsuda, Kengo Nagashima

|Nov 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.

Joseph Tintelnot, Lisa Paschold, Eray Goekkurt

|Mar 14, 2024
Reply to F. Salani et al.

Beate Rau, Peter C Thuss-Patience

|Nov 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience

|Oct 31, 2023
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.

Beate Rau, Hauke Lang, Alfred Koenigsrainer

Pageof 3

Frequent Collaborators

6 joint publications

Matthias Biebl

3 joint publications

Beate Rau

3 joint publications

Dino Kröll

3 joint publications

Jonas Raakow